This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wyckoff, J. A. Articles by Dluhy, R. G. Search for Related Content PubMed PubMed Citation Articles by Wyckoff, J. A. Articles by Dluhy, R. G. Pubmed/NCBI databases Medline Plus Health Information High Risk Pregnancy Related Collections Clinical genetics Other hypertension Other etiology

(Hypertension. 2000;35:668.)
© 2000 American Heart Association, Inc.

Scientific Contributions

Glucocorticoid-Remediable Aldosteronism and Pregnancy

Jennifer A. Wyckoff; Ellen W. Seely; Shelley Hurwitz; Bruce F. Anderson; Richard P. Lifton; Robert G. Dluhy

From the Endocrine Hypertension Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass, and Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, Conn (R.P.L.).

Correspondence to Robert G. Dluhy, MD, Endocrine Hypertension Division, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA 02115.

Abstract—Glucocorticoid-remediable aldosteronism (GRA) is a hereditary form of primary hyperaldosteronism that presents with hypokalemia and hypertension from childhood onward. GRA is characterized by the ectopic production of aldosterone in the cortisol-producing zona fasciculata under the regulation of adrenocorticotrophic hormone. Despite the early age of onset, no previous reports of pregnancy and GRA exist. Therefore, we set out to describe the maternal and fetal outcomes of pregnancy in women with GRA. Data regarding the blood pressure and pregnancy outcomes were collected in a retrospective chart review of prenatal and hospital records of 35 pregnancies in 16 women with genetically proven GRA. A total of 6% of pregnancies in women with GRA (GRA+) were complicated by preeclampsia. The published rates of preeclampsia in general obstetric populations vary from 2.5% to 10%. Despite the lack of an apparent increase in the rate of preeclampsia, GRA+ women with chronic hypertension had a high rate (39%) of pregnancy-aggravated hypertension. Starting with a higher baseline blood pressure, maternal blood pressure plotted over the time course of pregnancy followed a quadratic curve similar to that previously described in normal pregnancy. Mean gestational age at delivery was 39.1 weeks. Mean birth weight, excluding the 3 sets of twins, was 3219 g. However, infants of GRA+ mothers with pregnancy-aggravated hypertension tended to have lower birth weights than those that did not (3019 g versus 3385 g, respectively; P=0.08). The primary cesarean section rate was 32%, which is approximately double that seen in other general or hypertensive obstetric populations. In summary, GRA+ women did not seem to have an increased risk of preeclampsia. However, GRA+ women with chronic hypertension seem to be at an increased risk for an exacerbation of their hypertension during pregnancy.

Key Words: hypertension, chronic • pregnancy • blood pressure • hyperaldosteronism • renin-angiotensin system • glucocorticoids

This article has been cited by other articles:

				G. Escher Hyperaldosteronism in pregnancy Therapeutic Advances in Cardiovascular Disease, April 1, 2009; 3(2): 123 - 132. [Abstract] [PDF]

				P. Mulatero, S. M. di Cella, T. A. Williams, A. Milan, G. Mengozzi, L. Chiandussi, C. E. Gomez-Sanchez, and F. Veglio Glucocorticoid Remediable Aldosteronism: Low Morbidity and Mortality in a Four-Generation Italian Pedigree J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3187 - 3191. [Abstract] [Full Text] [PDF]